Astra Buying Bristol Makes No Sense, Fazeli Says

Bloomberg Intelligence Senior Pharmaceutical Analyst Sam Fazeli argues that the reported AstraZeneca–Bristol-Myers merger makes no strategic or financial sense for AstraZeneca. He cites AstraZeneca's strong growth outlook versus Bristol-Myers' patent-driven earnings decline, and dismisses the geographic access rationale. The market punished AstraZeneca shares on the news, and Fazeli sees the deal as value-destroying for AstraZeneca. - AstraZeneca and Bristol-Myers reportedly held early-stage merger talks, creating a potential $107bn revenue drugmaker. - AstraZeneca fell 7%, Bristol-Myers rose 2.7% on the news. - Sam Fazeli of Bloomberg Intelligence says the deal makes 'no sense' and would destroy value for AstraZeneca. - AstraZeneca has double-digit growth through 2030; Bristol-Myers faces flat or declining earnings from patent expiries. - The geographic-access justification is weak; both companies are already global. - Mega-mergers in pharma have historically been value-destructive, according to Fazeli. - The market reaction aligns with the analyst's view that the deal is negative for AstraZeneca.